Founded in 2018, NeoProgen specializes in biotechnology and cardiac therapy, focusing on advancing neonatal cardiac progenitor cells. The company's cell-based therapy is designed for people who experience a heart attack and patients with advanced heart failure. The therapy is developed from neonatal cardiac progenitor cells derived from tissue discarded during lifesaving heart surgery in babies with congenital heart conditions. Additionally, NeoProgen's sister company, Secretome Therapeutics, is developing a pipeline of secretome products to address diseases driven by inflammation and mitochondrial dysfunction.